2021
DOI: 10.7150/thno.66478
|View full text |Cite
|
Sign up to set email alerts
|

Microneedle arrays integrated with living organisms for smart biomedical applications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
17
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9
1

Relationship

4
6

Authors

Journals

citations
Cited by 23 publications
(17 citation statements)
references
References 143 publications
0
17
0
Order By: Relevance
“…Our results provide us with a better understanding of the characteristics of the immune pool in normal Chinese people and a method which provides a foundation to study age‐related diseases and monitor treatments, thus improving future treatments. This study shows the importance of conducting larger studies of repertoire analysis from different ages, populations, and health status, as this can be used as disease markers thus aiding in early diagnosis 52–55 and personalized treatment 56–60 …”
Section: Discussionmentioning
confidence: 95%
“…Our results provide us with a better understanding of the characteristics of the immune pool in normal Chinese people and a method which provides a foundation to study age‐related diseases and monitor treatments, thus improving future treatments. This study shows the importance of conducting larger studies of repertoire analysis from different ages, populations, and health status, as this can be used as disease markers thus aiding in early diagnosis 52–55 and personalized treatment 56–60 …”
Section: Discussionmentioning
confidence: 95%
“…Microneedles (MNs), which are basically needles in the scale of micrometers at most, are robustly growing [ 1 ] pioneers of the minimally invasive injection procedures, enabling more advanced delivery/collecting systems [ 2 , 3 ]. In comparison with conventional needle technologies, MNs are verified to be more advantageous by decreasing the administration pain [ 4 ] and curtailment of anxiety and needle phobia [ 5 ], along with being more cost-efficient for drug delivery [ 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…Hence parasite products are not considered for clinical application. To address the challenge of the immunotherapy of parasite-related products in T1DM, based on our previous success in microneedlebased strategies [39][40][41][42][43], herein we develop an asymmetric microneedle patch for the continuous and safe release Fig. 1 Immunological mechanism of STAMP application on the skin during the type 1 diabetes treatment.…”
Section: Introductionmentioning
confidence: 99%